Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.95 EUR | -0.75% | -7.17% | +6.33% |
Feb. 15 | Transcript : Optomed Oyj, 2023 Earnings Call, Feb 15, 2024 | |
Feb. 15 | Optomed Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- With an enterprise value anticipated at 4.24 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.33% | 75.84M | - | ||
+9.50% | 222B | B | ||
+7.95% | 185B | B- | ||
+18.30% | 141B | B- | ||
+18.47% | 100B | A- | ||
+7.83% | 68.36B | A- | ||
+25.32% | 57.52B | B+ | ||
-3.69% | 46.84B | B+ | ||
+4.66% | 42.64B | A | ||
+17.58% | 41.4B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock Optomed Oyj - Nasdaq Helsinki
- Ratings Optomed Oyj